Foley Hoag LLP recently advised global biopharmaceutical company Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) in a partnership with Complement Pharma to co-develop a pre-clinical C6 complement inhibitor for neurodegenerative disorders. Under the terms of the agreement, Alexion will provide Complement with up to €14 million in milestone payments. Alexion will also have the option to acquire Complement during the term of the agreement. Founded in 1992, Alexion’s global headquarters is based in New Haven, CT and its EMEA headquarters is based in Zurich, Switzerland. The company is an international leader in complement biology, focusing its research efforts on novel molecules and targets, and its development efforts on hematology, nephrology, neurology and metabolic disorders. Complement is a biotech company focused on C6 complement inhibition to modify neurodegenerative disease progression. It is developing a line of products based on proprietary monoclonal antibodies to inhibit formation of the Membrane Attack Complex (MAC), which is linked to traumatic brain injury and neurodegenerative disorders. Alexion and Complement will collaborate on the preclinical and Phase 1 studies and manufacturing for C6 complement inhibitor, CP010. CP010 is a humanized monoclonal antibody that binds to C6 in circulation to inhibit its function throughout the body by preventing MAC formation. Foley Hoag attorneys Mark Haddad, Sarah Cooleybeck and Corey Brown advised Alexion in the transaction.